Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: association with serotonin in brain regions

ABSTRACT

Outcome of imipramine [IMI] treatment was scrutinized on progression of haloperidol instigated tardive dyskinesia [TD]. 0.2 mg/kg/rat dosage of haloperidol provided orally to rats for 2 weeks enhanced vacuous chewing movements that escalated when the process proceeded for 5 weeks. Following 2 weeks co-injection 5 mg/kg dosage of IMI was diminished haloperidol-instigated VCMs and fully averted following five weeks. The potency of 8-OH-DPATinstigated locomotor activity exhibited higher in saline+haloperidol treated rats while not observed in IMI+ haloperidol treated rats. 8-OH-DPAT-instigated low 5-hydroxytryptamine [5-HT; serotonin] metabolism was higher in saline+ haloperidol treated rats when compare to IMI+ haloperidol treated rats in both regions of brain [striatum and midbrain]. It is recommended that IMI possibly competent in averting TD, in cases receiving treatment to antipsychotics